J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma
This article was originally published in The Gray Sheet
Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.
You may also be interested in...
News that Europe’s largest biotech Actelion is in preliminary discussions with Johnson & Johnson about a transaction has been viewed favourably by investors, and could see the return of mega-merger activity to other big pharma companies.
Zimmer has agreed to buy Biomet by the first quarter of 2015, furthering the trend of consolidation in the $45 billion orthopedic device industry. The companies had combined revenues of $7.8 billion in 2013.
PharmAsia News takes a closer look at J&J’s growth in key emerging markets.